PSMD11

Across TCGA pan-cancer cohorts, PSMD11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSMD11 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSMD11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PSMD11 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where PSMD11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.627	0.885	.009	10	view →
PDAC	DFS	Median	All	0.355	0.531	.031	8	view →
HNSC	DFS	Median	II,III,IV	0.863	0.694	.018	7	view →
CCRCC	OS	Quartile	III,IV	0.350	0.930	.014	5	view →
LSCC	DFS	Median	All	0.851	0.472	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSMD11–LUAD (OS)

Open the LUAD breakdown →